Please login to the form below

Not currently logged in
Email:
Password:

Affymax

This page shows the latest Affymax news and features for those working in and with pharma, biotech and healthcare.

Omontys terminal as Takeda switches off support

Omontys terminal as Takeda switches off support

As a result, Takeda says it will now withdraw its US marketing application for Omontys, as Affymax has indicated it would not take over rights to the drug. ... For Affymax, taking over Omontys was never a realistic option, even if Takeda had found a

Latest news

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Furthermore, earlier this year the company withdrew its marketing authorization application (MAA) in Europe for the Affymax-partnered anaemia treatment Omontys (peginesatide) and recalled all lots of the drug in the

  • Affymax in a tailspin after Omontys recall Affymax in a tailspin after Omontys recall

    Makes heavy job cuts in face of bankruptcy threat. Affymax is slashing three quarters of its workforce and could be facing bankruptcy in the wake of the recall last month of ... Analysts put the chances of Omontys returning to the market as slim, noting

  • Takeda-Affymax recall Omontys in US after deaths Takeda-Affymax recall Omontys in US after deaths

    Several deaths related to the kidney disease treatment Omontys have led to a recall of the injection in the US by Takeda and Affymax. ... The recall is voluntary at the moment, with Takeda and Affymax working with the US FDA.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest appointments

  • KaloBios names Herb Cross as CFO KaloBios names Herb Cross as CFO

    He joins from Affymax. Herb Cross is to join KaloBios as the company's new chief financial officer. ... Cross joins from biopharma company Affymax, where he was also chief financial officer.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    During his time at Affymax, Dr Polu headed several areas, including clinical sciences, clinical operations and drug safety/pharmacovigilance. ... Prior to this period at Affymax, Dr Polu was executive director, global development at Amgen, where he

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics